Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.75, $0.03 better than the analyst estimate of $2.72. Revenue for the quarter came in at $913.9 million versus the consensus estimate of $910.1 million.

GUIDANCE:

Charles River Laboratories sees FY2022 EPS of $11.50-$11.75, versus the consensus of $11.64.

• Revenue growth, reported 13.5% – 15.5%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.